Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EC-18
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EC-18 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 05, 2024
Lead Product(s) : EC-18
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EC-18 (mosedipimod) is immune modulator, has unique MOA called PETA which accelerates PRR-mediated endocytosis, endosome formation, ROS generation and recycle of PRR such TLR4 so that EC-18 duration of inflammatory immune response by removing PAMP associ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Mosedipimod
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary efficacy endpoint demonstrated that the median duration of SOM (defined as WHO Grades 3 or 4) from baseline through short-term follow-up period (STFU) was 0.0 days in the EC-18 group versus 13.5 days in the placebo group (100% reduction).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2022
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary efficacy endpoint demonstrated that the median duration of SOM from baseline through short-term follow-up period was 0.0 days in EC-18, an immunomodulator, group versus 13.5 days in the placebo group (100% reduction).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2022
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EC-18 is in clinical development in Phase 2 clinical trials in chemoradiation-induced oral mucositis and COVID-19. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase II trial of EC-18 is a synthetic monoacetyldiaglyceride treat oral mucositis in individuals with concomitant chemo-irradiation for mouth, hypopharynx, oropharynx, and nasopharynx cancers.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program
Details : Enzychem's lead compound, EC-18, is an immunomodulator that rapidly resolves inflammation and restores immune homeostasis by accelerating the intracellular trafficking of pattern recognition receptor-bound pathogenic invaders or endogenous danger signals...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 20, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Poster titled "First in-class, orally active Toll-like receptor signaling inhibitor mosedipimod (PLAG) attenuates molecular, biochemical and histologic features of nonalcoholic steatohepatitis (NASH) in vitro and in vivo" will be presented at the EASL Co...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 16, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Poster titled Titled "TLR Signaling Inhibition with Mosedipimod" will be presented at the conference. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosedipimod
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : NASA
Deal Size : $0.1 million
Deal Type : Funding
Details : NASA’s Human Research Program has awarded $150K in grant funding to conduct research on its lead compound EC-18, and how it impacts astronaut health and performance during future long-duration missions beyond low-Earth orbit.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 26, 2021
Lead Product(s) : Mosedipimod
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : NASA
Deal Size : $0.1 million
Deal Type : Funding